Human Stem Cells Institute

The Human Stem Cells Institute is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
Human Stem Cells Institute stock price chart
+234%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Human Stem Cells Institute balance sheet

Report period2016 2017 2018 2019 2020 Q2 21
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Human Stem Cells Institute cash flows

Report period2016 2017 2018 2019 2020 Q2 21 TTM
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Human Stem Cells Institute multipliers

Report period2016 2017 2018 2019 2020 Q2 21 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Human Stem Cells Institute profitability

Report period2016 2017 2018 2019 2020 Q2 21 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Human Stem Cells Institute assets
Human Stem Cells Institute cash flows
Human Stem Cells Institute dividends
0%

Human Stem Cells Institute shares

TickerNameTypeNominal valueISINPrice
ISKJ:RMHuman Stem Cells InstituteCommon shareRUB 0.1RU000A0JNAB6RUB 126.4

Human Stem Cells Institute bonds

NameIssue sizePriceYield
ISKJ BO-01300,000 pcs.RUB 99.539.27%
Share capital structure of Human Stem Cells Institute
Human Stem Cells Institute news
02.11.2021
Human Stem Cells Institute's RAS net income for 9M 2021 was ₽47.707 million, up 46.2% from ₽32.632 million in the previous year. Revenue increased 19.4% to ₽50.682 million compared to ₽42.459 million a year earlier.
15.10.2021
HSCI has begun Phase I-II clinical trials for the coronavirus vaccine Betuvax-CoV-2. The drug will be tested on 170 volunteers between the ages of 18 and 60. Participants will receive two components of the vaccine at 28-day intervals. The developers expect minimal side effects due to the characteristics of the composition. According to preclinical studies, t...
Source: {source} pictogram tass.ru
27.09.2021
HSCI has received approval from the Russian Ministry of Health to begin clinical trials of the coronavirus vaccine Betuvax-CoV-2. The drug consists of nanoparticles that mimic the SARS-CoV-2 coronavirus but are not capable of infecting mammals. Phase I and Phase II trials will run from September 27, 2021 to August 31, 2022.
Source: {source} pictogram ria.ru
22.09.2021
Board of Directors of Human Stem Cells Institute set the offering price of additional common shares at ₽80 per share. The company intends to place 12,500,000 shares by private subscription in favor of the International Medical Center for Biomaterials Processing and Cryopreservation.
General information
Company nameHuman Stem Cells Institute
Tags#biotechnology, #pharmacy
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websitehsci.ru
Information disclosuree-disclosure.ru